Clinical Pharmacology Considerations for Developing Small‐Molecule Treatments for COVID‐19-Reference-Cited by-同舟云学术

Clinical Pharmacology Considerations for Developing Small‐Molecule Treatments for COVID‐19

Published:2020-07-12 Issue:9 Volume:60 Page:1147-1154
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Brunsdon Priya¹,Saluja Bhawana¹,Sahajwalla Chandrahas¹

Affiliation:

1. Division of Inflammation and Immune PharmacologyOffice of Clinical PharmacologyOffice of Translational Sciences, Center for Drug Evaluation and ResearchU.S. Food and Drug Administration Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1697

Reference45 articles.

1. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

2. World Health Organization Geneva Switzerland Who Director‐General's Opening Remarks at the Media Briefing on Covid‐19 ‐ 11 March 2020

3. World Health Organization Geneva Switzerland Coronavirus

4. Mild or Moderate Covid-19

5. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expedited regulatory product approval in the time of COVID-19;The Ocular Surface;2022-10

2. Small molecules targeting endolysosomal acidification and signaling in sepsis and severe SARS-CoV-2 infection/COVID-19;Exploration of Immunology;2022-08-11

3. Eyes on New Product Development;Journal of Ocular Pharmacology and Therapeutics;2022-05-01

4. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases;Journal of Nanobiotechnology;2022-03-03

5. A revolution by recombinant DNA technology to improve the quality of life;Biomedical Letters;2021-02-05